BofA raised the firm’s price target on BioMarin (BMRN) to $103 from $99 and keeps a Buy rating on the shares following what the firm calls “solid top and bottom-line consensus beats.” The firm cites higher margins for its price target raise, adding that it sees an “undemanding valuation which ascribes minimal value to Voxzogo first-mover and franchise preservation strategies.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- Strong Financial Performance and Strategic Growth Drive Buy Rating for BioMarin Pharmaceutical
- BioMarin price target raised to $126 from $122 at Piper Sandler
- BioMarin price target raised to $82 from $81 at Citi
- BioMarin Pharmaceutical: Hold Rating Amid Strong Performance and Decelerating Growth Prospects
- BioMarin Pharmaceutical’s Strong Financial Performance and Growth Prospects Justify Buy Rating